Titre : Paralysie pseudobulbaire

Paralysie pseudobulbaire : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Activation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Paralysie pseudobulbaire : Questions médicales les plus fréquentes", "headline": "Paralysie pseudobulbaire : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Paralysie pseudobulbaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-02", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Paralysie pseudobulbaire" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Paralysie", "url": "https://questionsmedicales.fr/mesh/D010243", "about": { "@type": "MedicalCondition", "name": "Paralysie", "code": { "@type": "MedicalCode", "code": "D010243", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.888.592.636" } } }, "about": { "@type": "MedicalCondition", "name": "Paralysie pseudobulbaire", "alternateName": "Pseudobulbar Palsy", "code": { "@type": "MedicalCode", "code": "D020828", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Kenjiro Kunieda", "url": "https://questionsmedicales.fr/author/Kenjiro%20Kunieda", "affiliation": { "@type": "Organization", "name": "Neurology, Gifu University Graduate School of Medicine, Gifu, JPN." } }, { "@type": "Person", "name": "Tomohisa Ohno", "url": "https://questionsmedicales.fr/author/Tomohisa%20Ohno", "affiliation": { "@type": "Organization", "name": "Dentistry, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN." } }, { "@type": "Person", "name": "Ichiro Fujishima", "url": "https://questionsmedicales.fr/author/Ichiro%20Fujishima", "affiliation": { "@type": "Organization", "name": "Rehabilitation Medicine, Hamamatsu City Rehabilitation Hospital, Hamamatsu, JPN." } }, { "@type": "Person", "name": "Victor Kekere", "url": "https://questionsmedicales.fr/author/Victor%20Kekere", "affiliation": { "@type": "Organization", "name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA." } }, { "@type": "Person", "name": "Patrice Fouron", "url": "https://questionsmedicales.fr/author/Patrice%20Fouron", "affiliation": { "@type": "Organization", "name": "Psychiatry, Interfaith Medical Center, Brooklyn, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots.", "datePublished": "2024-06-12", "url": "https://questionsmedicales.fr/article/38933264", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1368852" } }, { "@type": "ScholarlyArticle", "name": "Synthetic Oligodeoxynucleotide CpG Motifs Activate Human Complement through Their Backbone Structure and Induce Complement-Dependent Cytokine Release.", "datePublished": "2022-09-14", "url": "https://questionsmedicales.fr/article/36104112", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4049/jimmunol.2101191" } }, { "@type": "ScholarlyArticle", "name": "Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays.", "datePublished": "2023-02-11", "url": "https://questionsmedicales.fr/article/36816333", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2147/IJN.S384184" } }, { "@type": "ScholarlyArticle", "name": "Modeling complement activation on human glomerular microvascular endothelial cells.", "datePublished": "2023-10-25", "url": "https://questionsmedicales.fr/article/37954621", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1206409" } }, { "@type": "ScholarlyArticle", "name": "Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.", "datePublished": "2022-07-16", "url": "https://questionsmedicales.fr/article/35853795", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.smim.2022.101640" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Signes et symptômes", "item": "https://questionsmedicales.fr/mesh/D012816" }, { "@type": "ListItem", "position": 4, "name": "Manifestations neurologiques", "item": "https://questionsmedicales.fr/mesh/D009461" }, { "@type": "ListItem", "position": 5, "name": "Paralysie", "item": "https://questionsmedicales.fr/mesh/D010243" }, { "@type": "ListItem", "position": 6, "name": "Paralysie pseudobulbaire", "item": "https://questionsmedicales.fr/mesh/D020828" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Paralysie pseudobulbaire - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Paralysie pseudobulbaire", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Paralysie pseudobulbaire", "description": "Comment diagnostique-t-on la paralysie pseudobulbaire ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels symptômes aident au diagnostic ?\nLa paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?\nPeut-on confondre cette paralysie avec d'autres troubles ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+Activation&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Paralysie pseudobulbaire", "description": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?\nLa difficulté à parler est-elle un symptôme courant ?\nLes patients ressentent-ils de la douleur ?\nY a-t-il des variations dans les symptômes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+Activation&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Paralysie pseudobulbaire", "description": "Peut-on prévenir la paralysie pseudobulbaire ?\nComment réduire le risque de paralysie pseudobulbaire ?\nLes AVC peuvent-ils être prévenus ?\nLa réhabilitation précoce aide-t-elle à prévenir la paralysie ?\nLes habitudes alimentaires influencent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+Activation&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Paralysie pseudobulbaire", "description": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?\nLa rééducation est-elle utile ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces pour tous les patients ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+Activation&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Paralysie pseudobulbaire", "description": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?\nLa dépression est-elle une complication fréquente ?\nLes complications affectent-elles la qualité de vie ?\nY a-t-il des risques d'isolement social ?\nLes complications peuvent-elles être traitées ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+Activation&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Paralysie pseudobulbaire", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque de paralysie pseudobulbaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie peut-il influencer le risque ?\nLes maladies cardiovasculaires sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D020828?mesh_terms=Complement+Activation&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostique-t-on la paralysie pseudobulbaire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'évaluation des symptômes neurologiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests d'imagerie cérébrale comme l'IRM peuvent être utilisés pour identifier les lésions." } }, { "@type": "Question", "name": "Quels symptômes aident au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des accès de rire ou de pleurs inappropriés et des troubles de la parole." } }, { "@type": "Question", "name": "La paralysie pseudobulbaire est-elle toujours associée à d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent associée à des maladies neurologiques comme la sclérose en plaques ou les AVC." } }, { "@type": "Question", "name": "Peut-on confondre cette paralysie avec d'autres troubles ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec d'autres troubles affectant le contrôle émotionnel et moteur." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes de la paralysie pseudobulbaire ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux symptômes incluent des crises de rire ou de pleurs incontrôlables." } }, { "@type": "Question", "name": "La difficulté à parler est-elle un symptôme courant ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent éprouver des difficultés à articuler et à contrôler leur voix." } }, { "@type": "Question", "name": "Les patients ressentent-ils de la douleur ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La paralysie pseudobulbaire ne cause généralement pas de douleur physique, mais des malaises émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des variations dans les symptômes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en intensité et en fréquence d'un patient à l'autre." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avec le temps ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les symptômes peuvent s'aggraver et affecter la qualité de vie." } }, { "@type": "Question", "name": "Peut-on prévenir la paralysie pseudobulbaire ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais la gestion des maladies sous-jacentes peut aider." } }, { "@type": "Question", "name": "Comment réduire le risque de paralysie pseudobulbaire ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain et traiter les affections neurologiques peut réduire le risque." } }, { "@type": "Question", "name": "Les AVC peuvent-ils être prévenus ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en contrôlant les facteurs de risque comme l'hypertension et le diabète, on peut réduire les AVC." } }, { "@type": "Question", "name": "La réhabilitation précoce aide-t-elle à prévenir la paralysie ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une réhabilitation précoce après un AVC ou une lésion cérébrale peut aider à prévenir la paralysie." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles le risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut contribuer à la santé neurologique et réduire les risques." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la paralysie pseudobulbaire ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des médicaments comme les antidépresseurs et la thérapie comportementale." } }, { "@type": "Question", "name": "La rééducation est-elle utile ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la rééducation orthophonique peut aider à améliorer les capacités de communication." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils réduire les symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent réduire la fréquence et l'intensité des épisodes émotionnels." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des approches comme la thérapie psychologique peuvent également être bénéfiques." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces pour tous les patients ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité des traitements peut varier selon les individus et la gravité des symptômes." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la paralysie pseudobulbaire ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles de la déglutition et des problèmes de communication." } }, { "@type": "Question", "name": "La dépression est-elle une complication fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent développer une dépression en raison de l'impact émotionnel de la maladie." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement altérer la qualité de vie des patients." } }, { "@type": "Question", "name": "Y a-t-il des risques d'isolement social ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les difficultés de communication peuvent entraîner un isolement social pour les patients." } }, { "@type": "Question", "name": "Les complications peuvent-elles être traitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées avec des traitements appropriés et un soutien." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les AVC, les maladies neurodégénératives et les traumatismes crâniens sont des facteurs de risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de paralysie pseudobulbaire ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque augmente avec l'âge, surtout chez les personnes âgées ayant des antécédents médicaux." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies neurologiques peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le mode de vie peut-il influencer le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque." } }, { "@type": "Question", "name": "Les maladies cardiovasculaires sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies cardiovasculaires augmentent le risque de paralysie pseudobulbaire par AVC." } } ] } ] }

Sources (10000 au total)

Synthetic Oligodeoxynucleotide CpG Motifs Activate Human Complement through Their Backbone Structure and Induce Complement-Dependent Cytokine Release.

Bacterial and mitochondrial DNA, sharing an evolutionary origin, act as danger-associated molecular patterns in infectious and sterile inflammation. They both contain immunomodulatory CpG motifs. Inte...

Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays.

The role of the human immune system in pathologic responses to chemicals including nanomaterials was identified as a gap in current hazard assessments. However, the complexity of the human immune syst... We treated commercially available pooled sera (PS) from healthy males, individual sera from healthy donors and from patients suffering from cancer, immunodeficiency and allergies with small molecules ... The level of complement activation in PS differed significantly from responses of individual donors (p < 0.01). Only seven out of 32 investigated sera from healthy donors responded similarly to the po... Our studies demonstrate that the use of pooled serum can lead to an over- or under-estimation of immunological response in particular for individuals with pre-existing pathologies. This is of high rel...

Modeling complement activation on human glomerular microvascular endothelial cells.

Atypical hemolytic uremic syndrome (aHUS) is a rare kidney disease caused by dysregulation of the complement alternative pathway. The complement dysregulation specifically leads to damage to the glome... Endothelial cells were incubated with human test sera and stained with an anti-C5b-9 antibody to visualize and quantify complement depositions on the cells with immunofluorescence microscopy.... First, we showed that zymosan-activated sera resulted in increased endothelial C5b-9 depositions compared to normal human serum (NHS). The levels of C5b-9 depositions were similar between conditionall... In conclusion, we demonstrate a robust and reliable model to adequately measure C5b-9-based complement deposition on human control and patient ciGMVECs. This model can be used to study the pathophysio...

DAMPS and complement activation in platelet concentrates that induce adverse reactions in patients.

Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of... Single donor apheresis platelet concentrates (SDA PCs) were produced in a regional setting of the French Blood Establishment. After transfusion samples were collected from PC and possible AR in patien... A total of 56 PC were included in the study. 30 PC induced no AR, and 26 induced AR (Febrile non-hemolytic transfusion reaction n = 16; Atypical Allergic Transfusion Reactions n = 11; hemodynamic inst... In this study, we observed an association between HMGB1 and CAP and the incidence of AR. Furthermore, we demonstrated that both HMGB1 and complement activation were correlated to platelet activation....

Minimal role for the alternative pathway in complement activation by HIT immune complexes.

Anti-platelet factor 4 (PF4)/heparin immune complexes that cause heparin-induced thrombocytopenia (HIT) activate complement via the classical pathway. Previous studies have shown that the alternative ... These studies sought to examine the contributions of the alternative pathway to complement activation by HIT antibodies.... Using IgG monoclonal (KKO) and/or patient-derived HIT antibodies, we compared the effects of classical pathway (BBK32 and C1-esterase inhibitor [C1-INH]), alternative pathway (anti-factor B [fB] or fa... Classical pathway inhibitors BBK32 and C1-INH and the combined classical/alternative pathway inhibitor sCR1 prevented KKO/HIT immune complex-induced complement activation, including release of C3 and ... Collectively, these findings suggest the alternative pathway contributes little in support of complement activation by HIT immune complexes. Additional in vitro and in vivo studies are required to exa...